In the latest market close, Moderna (MRNA) reached $54.36 ... Meanwhile, the Dow lost 0.9%, and the Nasdaq, a tech-heavy index, lost 2.76%. The biotechnology company's shares have seen a decrease ...

Avidity Biosciences stock surges on expansion of pipeline targeting rare genetic cardiomyopathies and improvements in siRNA ...

Moderna (MRNA) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook gives ...

Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals ...

We recently published a list of 10 Most Promising Gene Editing Stocks to Buy According to Hedge Funds. In this article, we ...

In trading on Monday, shares of Moderna Inc (Symbol: MRNA) entered into oversold territory, hitting an RSI reading of 29.3, after changing hands as low as $53.41 per share. By comparison ...

Pharmaceutical company Moderna (MRNA) has seen its stock slump in recent months. The share price peaked at $150 in early ...

U.S. stocks were higher after the close on Monday, as gains in the Consumer Goods, Financials and Industrials sectors led ...

Moderna (NASDAQ:MRNA – Get Free Report) had its price objective dropped by research analysts at Barclays from $125.00 to $111 ...

Wave Life Sciences Ltd. (NASDAQ:WVE) Q3 2024 Earnings Call Transcript November ... These targets include PNPLA3 where we are ...

About Arcturus Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a commercial mRNA medicines and vaccines company with enabling technologies: (i ...